Novo valuation surpasses Tesla on experimental obesity drug data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK1,054 at TD Cowen
March 11, 2024 2:03 PM EDTTD Cowen analyst Steve Scala raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK1,054.00 (from DKK925.00) while maintaining a Outperform rating.
The analyst comments "Novo announced FDA approval of the expanded label for Wegovy, now indicated to reduce CV risk in people with both obesity and CVD based on data from SELECT. Though these data are widely appreciated by specialists after... More
Jefferies starts Viking Therapeutics (VKTX) at buy on 'scarcity value'
March 7, 2024 1:59 PM ESTJefferies initiated Viking Therapeutics (NASDAQ: VKTX) with a Buy rating and $110 per share price target in a note Thursday, telling investors the company is a strong mid-stage obesity player with scarcity value.
VKTX is developing subQ/oral VK2735 (GLP-1/GIP) for obesity,... More
